Trial Profile

Phase I, Non-randomised, Open-label, Multi-centre Dose Escalation and Expansion Trial of BI 765049 and BI 765049 + Ezabenlimab Administered by Repeated Intravenous Infusion in Asian Patients With Malignant Solid Tumours Expressing B7-H6

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BI 765049 (Primary) ; Ezabenlimab (Primary)
Indications Adenocarcinoma; Colorectal cancer; Ductal carcinoma; Gastric cancer; Gastrointestinal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Boehringer Ingelheim

04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
13 Feb 2024 Status changed from not yet recruiting to recruiting.
25 Jan 2024 Planned End Date changed from 4 Feb 2027 to 11 Feb 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com